SecBot SecBot
PRESS-RELEASE ·Filed Mar 30, 2026

RVPH

Reviva Pharmaceuticals
MIXED
Impact 6/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The narrower loss and extended cash runway are positive, but the FDA's requirement for a second Phase 3 trial delays potential NDA submission and commercialization, increasing development costs and dilution risk. Monitor RECOVER-2 trial design and funding needs ahead of mid-2026 initiation.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.6600
T+0 close · Mar 30, 2026 · via day close
Latest settled
−9.09%
T+60 · $0.6000
Vs SPY
−25.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 30 $0.6600entry
  2. T+1 · 8mo ago +10.61%α +7.72% · $0.7300
  3. T+5 · 7mo ago +18.18%α +13.88% · $0.7800
  4. T+20 · 7mo ago +33.33%α +20.74% · $0.8800
  5. T+60 · 5mo ago −9.09%α −25.58% · $0.6000
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Reviva Pharmaceuticals reported financial results for 2025, showing a reduced net loss of $19.9M compared to $29.9M in 2024, with cash of $14.4M as of year-end. The company received FDA feedback requiring a second Phase 3 trial (RECOVER-2) for brilaroxazine in schizophrenia, planned to start mid-2026, and raised $23M in cash through equity offerings, extending its runway into Q1-2027.

Key Financial Metrics

EPS
$-5.48

Key Facts

  • Net loss narrowed to $19.9M in 2025 from $29.9M in 2024, with EPS improving from -$17.73 to -$5.48
  • Cash and cash equivalents increased to $14.4M as of December 31, 2025, up from $13.5M in 2024
  • FDA recommended a second Phase 3 trial (RECOVER-2) for brilaroxazine before NDA submission, delaying potential approval
  • RECOVER-2 trial initiation planned for mid-2026, with U.S. enrollment expected to begin in Q3-2026
  • Raised $23M in gross proceeds from three public offerings in 2025 and March 2026, giving ~$23M in cash post-March 2026 offering

Financial Impact

Reduced operating expenses by $10.6M YoY, primarily due to lower R&D spending; cash runway extended into Q1-2027

net losscashR&D expensedilution

Risk Factors

  • Clinical trial delay increases time to potential approval and risk of further regulatory hurdles
  • Dilution risk remains elevated given reliance on equity financing and projected cash runway into only Q1-2027

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3264432

Track record

12 reports on RVPH

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +22.98% at T+20 after the Jul 10, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 3/10 No price data
  2. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.3400 Now $0.3504 +3.07% settles Feb 11
  3. Nov 9, 20267d ago DEF 14A Neutral 4/10 Entry $0.3521 Now $0.3504 −0.47% settles Feb 8
  4. Aug 12, 202613w ago Press Release Neutral 4/10 Entry $0.3521 to $0.3521 Now $0.3504 −0.47% · 0.00% +5.48% vs SPY
  5. Jul 10, 202618w ago 25-NSE Bearish 7/10 Entry $0.6200 to $0.5000 Now $0.3504 +43.48% ▲ +19.35% +22.24% vs SPY
  6. May 13, 202626w ago Press Release Bearish 7/10 Entry $0.3900 to $0.4303 Now $0.3504 +10.14% ▼ −10.33% −6.74% vs SPY
  7. May 13, 202626w ago 8-K Bearish 8/10 Entry $0.3521 to $0.4775 Now $0.3504 +0.47% ▼ −35.62% −31.19% vs SPY
  8. Apr 15, 202630w ago 8-K Neutral 5/10 Entry $0.8900 to $0.5731 Now $0.3504 −60.62% ▼ −35.61% −43.74% vs SPY
  9. Mar 30, 202633w ago Press Release Mixed 6/10 Viewing Entry $0.6600 to $0.6000 Now $0.3504 −46.90% ▼ −9.09% −25.58% vs SPY
  10. Mar 18, 202634w ago Press Release Bearish 6/10 Entry $0.8300 to $0.7000 Now $0.3504 +57.78% ▲ +15.66% +30.01% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (11h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 30, 2026